12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients

Phase 3

Completed

Brief Summary: This was an open-label, extension trial designed to evaluate the long-term safety over 12 months of TNX-102 SL tablets taken daily at bedtime for the treatment of fibromyalgia. Patients recruited into this trial were those who had successfully completed the double-blind study, TNX-CY-F202 (F202) (NCT01903265). Patients were not made aware of the therapy they received during the double-blind study.

Detailed Description: The study consisted of 7 clinic visits, including Screening/Baseline Visit 1 (Day 0 which was typically the same date as Visit 6 of the double-blind lead-in study), visits after 1, 3, 6, 9, and 12 months of treatment (Visits 2-6), and a Follow-up Visit (Visit 7) scheduled within one month after stopping study drug treatment.

Primary:

The primary objective of the study was to evaluate the long-term safety of TNX-102 SL tablets taken daily at bedtime over 12 months in patients with fibromyalgia who have completed Study TNX-CY-F202 (NCT01903265)

Secondary:

The secondary objective was to evaluate the long-term efficacy of TNX-102 SL tablets taken daily at bedtime to control symptoms of fibromyalgia

Recruitment & Eligibility

Inclusion Criteria

The patient met all prior inclusion and exclusion requirements for Study F202 (NCT01903265) originally, and has had no intervening medical conditions, increased suicidal ideation, or requirements for concomitant medications that preclude exposure to TNX-102 SL or enrollment in the extension study.
The patient completed expected dosing in F202 (NCT01903265) defined as taking study medication up to Week 12, with at least 70% compliance with medication usage (based on responses from daily IVRS calls recorded during the F202 study (NCT01903265)) and no major protocol violations.
The patient has provided written informed consent to participate in this extension protocol.

Exclusion Criteria

None

Arm && Interventions

Group	Intervention	Description
TNX-102 SL	TNX-102 SL	1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months

Primary Outcome Measures

Name	Time	Method
Newly-emergent Adverse Events (NEAEs) During Treatment With TNX-102 SL Tablets Taken Daily at Bedtime Over 12 Months in Patients With Fibromyalgia.	Up to 12 months	NEAEs and Serious Adverse events (SAEs) were collected and are coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA).

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on 24 Hour Recall	Months 1, 3, 6, 9 and 12.	The NRS for average pain was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 24-hour recall basis.
Change From Baseline in Numerical Rating Scale (NRS) Assessments of Average Pain Based on a 7 Day Recall	Month 1, 3, 6, 9, 12	The NRS for average pain over the past 7 days was an 11-point scale (0=no pain → 10=worst pain imaginable) that was assessed on a 7-day recall basis.
Responder Analysis of Patient's Global Impression of Change (PGIC)	Months 1, 3, 6, 9, 12	PGIC is a fibromyalgia-specific validated instrument to gauge the patient's assessment of change in condition.The scores are categorized as provided below. A responder was defined by a score of 1 (very much improved), or 2 (much improved). 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse

Locations (13): 71 Thomas Johnson Drive
🇺🇸
Frederick, Maryland, United States
370 Faunce Corner Road
🇺🇸
North Dartmouth, Massachusetts, United States
Jackson
🇺🇸
Jackson, Mississippi, United States
322 Memorial Drive
🇺🇸
Greer, South Carolina, United States
Worcester
🇺🇸
Worcester, Massachusetts, United States
1275 Olentangy River Road
🇺🇸
Columbus, Ohio, United States
16176 Cortez Boulevard
🇺🇸
Brooksville, Florida, United States
Denver
🇺🇸
Denver, Colorado, United States
100 West Gore Street
🇺🇸
Orlando, Florida, United States
18660 Bagley Road
🇺🇸
Middleburg Heights, Ohio, United States
Cincinnati
🇺🇸
Cincinnati, Ohio, United States
601 Broadway
🇺🇸
Seattle, Washington, United States
1001 South Market Street
🇺🇸
Mechanicsburg, Pennsylvania, United States